

Differential expression of immunoregulatory genes in monocytes in response to *Porphyromonas gingivalis* and *Escherichia coli* lipopolysaccharide

H. E. Barksby, C. J. Nile,
K. M. Jaedicke, J. J. Taylor and
P. M. Preshaw

Periodontal Immunobiology Research Group,
School of Dental Sciences, Institute of Cellular
Medicine, Newcastle University, Newcastle upon
Tyne, UK

Summary

Porphyromonas gingivalis lipopolysaccharide (LPS) (strain W50) interacts with Toll-like receptor 2 (TLR-2) leading to cytokine expression and inflammation, and thereby plays a key role in the pathogenesis of periodontal disease. The aims of this study were to investigate gene expression of key regulatory mediators of innate immune responses in a human monocytic cell line (THP-1) to *P. gingivalis* LPS and to compare these results with those obtained using the TLR-4 ligand, *Escherichia coli* LPS. Custom-made Taqman low-density arrays were used for expression profiling of 45 different cytokine-related genes. Both types of LPS highly up-regulated interleukin (IL)-1 α and IL-1 β , IL-18 receptor (IL-18R), IL-18R accessory protein and IL-1 family (IL-1F)9. Expression levels of IL-1F6, IL-1F7 and caspase-1 were unaltered by either LPS. Genes for tumour necrosis factor- α , IL-6, leukaemia inhibitory factor and IL-32 were also highly induced by both LPS. For a subset of genes, including CXC chemokine ligand 5 (CXCL5), expression was induced only by *E. coli* LPS or was up-regulated more highly by *E. coli* compared with *P. gingivalis* LPS in THP-1 monocytes. A similar expression pattern was also observed in dendritic cells. Analysis of signalling pathways which lead to CXCL5 expression indicated that the mechanisms underpinning the differential responses did not involve the recruitment of different adaptor proteins by TLR-2 and TLR-4, and therefore occur downstream of the receptor-adaptor complex. We conclude that differences in signalling pathways activated by TLR-2 and TLR-4 ligands lead to differential innate immune responses which may be important in polymicrobial diseases such as periodontal disease.

Keywords: chemokines, cytokines, monocytes, PAMPS, *P. gingivalis*

Accepted for publication 12 February 2009

Correspondence: Dr P. Preshaw, Periodontal Immunobiology Research Group, School of Dental Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4BW, UK.

E-mail: p.m.preshaw@ncl.ac.uk

Introduction

Porphyromonas gingivalis is a key periodontal pathogen associated with the aetiology of periodontal disease [1]. The host inflammatory response in the periodontal tissues induced by bacteria and their components present in dental plaque leads to breakdown of the attachment apparatus between the tooth and the supporting bone and may result ultimately in tooth loss [1]. In addition, epidemiological evidence is now emerging which shows that periodontal disease may be linked to systemic disorders such as atherosclerosis and type 2 diabetes mellitus [2,3].

The innate immune system constitutes the first line of defence against periodontal pathogens. Monocytes play a critical part in this response, migrating to sites of infection

and undergoing differentiation into macrophages and dendritic cells which are involved in phagocytosis and the recruitment of the adaptive immune system through antigen presentation. Toll-like receptors (TLRs) are a major group of pattern recognition receptors involved in the detection of bacterial pathogen-associated molecular patterns (PAMPS). Lipopolysaccharide (LPS) derived from enteric bacteria such as *Escherichia coli* binds to TLR-4 leading to activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) and mitogen-activated protein kinase (MAPK) pathways and the production of proinflammatory cytokines [4]. LPS from *P. gingivalis* is structurally distinct from other types of LPS, such as *E. coli*, and has been shown to interact with both TLR-2 or TLR-4 [5–7]. Highly purified *P. gingivalis* LPS was found to contain two related

but distinct isoforms which differed in the lipid A moieties [5,7]. Therefore, distinct molecular forms of *P. gingivalis* LPS may activate TLR-2 and TLR-4 [5]. LPS from *P. gingivalis* strain W50 has been well characterized [8,9] and we have confirmed that it is a TLR-2-specific ligand (unpublished data). Interaction between TLRs and their ligands leads to the recruitment of adaptor proteins to the cytoplasmic domains of the TLRs [10]. The adaptors MyD88 and MyD88 adaptor-like mediate downstream activation of the NF- κ B, c-Jun N-terminal kinase (JNK) and p38 MAPK intracellular signalling pathways [11,12]. The MyD88-dependent pathway can also activate several members of the interferon regulatory factor (IRF) family of transcription factors, including IRF5 [10]. MyD88 is utilized by all the TLRs except TLR-3 to activate intracellular signalling cascades [13]. TLR-4 can also signal via a MyD88-independent pathway using the Toll/interleukin (IL)-1 receptor domain-containing adaptor inducing IFN- γ (TRIF) which is recruited via the TRIF-related adaptor molecule (TRAM) leading to NF- κ B, MAPK and IRF3 activation [14].

Host immune responses mediated through TLRs are dependent not only upon specific receptors binding but also on the nature of the receptor–ligand interaction. For example, fimbriae and LPS from *P. gingivalis* both interact with TLR-2; however, human macrophages display differential gene expression profiles in response to these stimuli [6,15,16]. Other studies have shown that different structural components of PAMPS interact with various accessory proteins modulating the TLR-mediated response [17]. This upstream mechanism has been demonstrated in monocytes/macrophages treated with fimbrial peptides. Thus, distinct fimbrial epitopes interact with CD14 or the β -integrin CD11b/CD18 which results in distinct cytokine expression profiles [17].

Differential activation of TLRs by PAMPS such as LPS leads to the activation of different intracellular signalling pathways, recruitment of transcription factors and the production of different repertoires of cytokines and other inflammatory mediators [15]. In a mixed infection such as periodontal disease, differential regulation of genes encoding inflammatory cytokines and associated molecules may have an impact on disease pathogenesis. The aims of this study were to investigate the temporal regulation of immunoregulatory genes in response to *P. gingivalis* LPS (a TLR-2 ligand), to compare gene expression induced by *P. gingivalis* and *E. coli* LPS (a TLR-4 ligand) and to identify genes which were regulated differentially in response to these PAMPS.

Materials and methods

Reagents

Unless stated otherwise, all laboratory reagents were purchased from Sigma (Poole, UK). *P. gingivalis* LPS (strain W50) was a gift from Dr M. Rangarajan, Barts and the London

School of Medicine and Dentistry, London, UK. *E. coli* LPS (strain 0111:B4) and monophosphoryl lipid A (MPLA) were purchased from Invivogen (San Diego, CA, USA). Experiments using HEK-293 cells stably transfected with either TLR-2 or TLR-4 confirmed that *P. gingivalis* (strain W50) was a specific TLR-2 agonist (Jaedicke, unpublished data).

Human monocyte (THP-1) cell culture

Human pro-monocytic THP-1 cells were purchased from the European Collection of Cell Cultures (Salisbury, Wilts, UK). Cells were cultured in RPMI-1640 medium, supplemented with fetal calf serum (FCS) (10% v/v), L-glutamine (2 mM), penicillin (100 U/ml) and maintained at 37°C and 5% CO₂. Prior to use, 4×10^6 THP-1 cells per well were differentiated into monocytes in six-well plates using 0.1 μ M 1,25 dihydroxyvitamin D3 (Merck Biosciences, Nottingham, UK) for 24 h [18]. After 24 h the ability of the cells to adhere to the plastic tissue culture dish (indicative of differentiation from pro-monocytes to monocytes) was assessed by microscopy. Cell viability was assessed by Trypan blue exclusion.

Isolation and culture of peripheral blood monocytes

Buffy coats obtained from the National Blood Service (Newcastle upon Tyne, UK) were mixed in a 1:1 ratio with phosphate-buffered saline (PBS)/ethylenediamine tetraacetic acid (EDTA) (5 mM), then layered on top of an equal volume of Histopaque (Sigma). Following centrifugation (300 g for 20 min), the buffy coat layer was removed and mixed with an equal volume of PBS/EDTA (5 mM). The cells were pelleted at 300 g (5 min) and the supernatant was discarded. To remove erythrocyte contamination, cells were resuspended in erythrocyte lysis buffer (150 mM NH₄Cl, 10 mM KHCO₃, 0.1 mM EDTA, pH 7.3) for 3 min before quenching in 10 ml PBS for 10 min. Platelets were removed by resuspending the cells in PBS/EDTA (2 mM) and centrifuged at 300 g for 10 min. Peripheral blood mononuclear cells within the buffy coat were counted prior to incubation in six-well plates at 1×10^6 cells/well. Cells were incubated for 12 h in RPMI-1640 medium, the non-adherent cells (lymphocytes) were removed and the adherent cells were gently washed twice in media. Fluorescence-activated cell sorting (FACS), using a CD14/fluorescein isothiocyanate-conjugated antibody, confirmed that the isolated cells were monocytes (data not shown). The purity of the monocyte populations was between 75 and 82% in all experiments.

Differentiation of peripheral blood monocytes into dendritic cells

Monocyte-derived dendritic cells (MDDCs) were produced by plating peripheral blood monocytes at 5×10^5 cells/ml in six-well plates in RPMI-1640 medium supplemented with IL-4 (50 ng/ml) and granulocyte–macrophage colony-stimulating factor (GM-CSF) (10 ng/ml) for 7 days [19].

Differentiation was confirmed by observing morphological changes using light microscopy. Changes in expression of CD1a, CD11C, CD14, human leucocyte antigen D-related and CD83 were measured by FACS to determine the phenotype of MDDCs prior to experimentation (data not shown).

Cell stimulation experiments

All assays measuring gene expression or secreted protein levels were performed following stimulation of cells with LPS or MPLA. Previous studies have demonstrated that monocytes are highly responsive to *P. gingivalis* LPS (strain W50), and maximal induction of tumour necrosis factor (TNF)- α expression was observed following treatment with 100 ng/ml *P. gingivalis* LPS [18,20]. Relevant controls were also measured in parallel. *E. coli*, *P. gingivalis* LPS (100 ng/ml) or MPLA (1 μ g/ml) were used to stimulate 1×10^6 cells/ml or 5×10^5 cells/ml (MDDCs) in six-well plates for 0.5 to 48 h.

RNA extraction and reverse transcription

Total RNA was isolated from myeloid cells using a RNeasy Mini Kit (Qiagen, Crawley, UK). The cells were lysed directly *in situ* using RLT buffer (Qiagen). RNA was isolated according to the manufacturer's instructions and was eluted in RNase-free water (30 μ l). Total RNA (1 μ g) was then reverse transcribed using random hexamers in 20 μ l reactions using a high capacity cDNA kit (Applied Biosystems, Warrington, UK) (ABI) according to the manufacturer's instructions.

Gene expression assays

Custom-made *Taqman* low-density arrays (TLDA) (ABI) were used for expression profiling based on real-time quantitative reverse transcription–polymerase chain reaction (RT–PCR) to compare the gene expression induced by *P. gingivalis* or *E. coli* LPS with unstimulated THP-1 monocytes. These arrays contained predesigned primers and *Taqman* probes (FAMTM reporter dye at the 5' end of each *Taqman*[®] MGB probe and a non-fluorescent quencher at the 3' end). Each array contained eight sample loading ports and 2.5 μ l of each 20 μ l cDNA reaction was loaded into each port. These arrays contained primers and probes for 45 different cytokine-related genes which regulate inflammatory processes (Table 1). RNA polymerase was used as endogenous control. Amplification and real-time analysis of cDNA samples loaded onto the TLDA were performed using an ABI 7900HT real-time PCR machine. The results were analysed using SDS version 2.2 software (ABI). Single-assay real-time RT–PCR using *Taqman* primers and probes (ABI) were performed for CXCL5 chemokine ligand 5 (CXCL5) (Hs00171085) to confirm the results obtained from the arrays. RNA polymerase II (Hs00172187_ml) was used as an endogenous control.

Table 1. Primers and probes for the quantification of gene expression using *Taqman* low-density arrays (TLDA).

Inflammatory mediator	Primers and probe assay ID
IL-1 α (interleukin-1 alpha)	Hs00174092_ml
IL-1 β (interleukin-1 beta)	Hs00174097_ml
IL-Ra (interleukin-1 receptor antagonist)	Hs00277299_ml
IL-1R1 (interleukin-1 receptor-1)	Hs00168392_ml
IL-1Acp (interleukin-1 accessory protein)	Hs00370506_ml
ICE (IL-1 converting enzyme) (caspase-1)	Hs00354836_ml
IL-18 (interleukin-18)	Hs00155517_ml
IL-18R1 (interleukin-18 receptor)	Hs00175381_ml
IL-18Acp (interleukin-1 accessory protein)	Hs00187256_ml
IL-1F6 (interleukin-1 family 6)	Hs00205367_ml
IL-1F7 (interleukin-1 family 7)	Hs00367199_ml
IL-1F8 (interleukin-1 family 8)	Hs00758166_ml
IL-1F9 (interleukin-1 family 9)	Hs00219742_ml
IL-1F10 (interleukin-1 family 10)	Hs00544661_ml
IL-1Rrp2 (IL-1 receptor-related protein 2)	Hs00187259_ml
TNF- α (tumour necrosis factor alpha)	Hs00174128_ml
TNFRSF1A (TNF alpha receptor superfamily 1A)	Hs00236902_ml
TNFRSF1B (TNF alpha receptor superfamily 1B)	Hs00153550_ml
TACE (TNF- α converting enzyme)	Hs00234221_ml
IL-4 (interleukin-4)	Hs00174122_ml
IL-6 (interleukin-6)	Hs00174131_ml
OSM (oncostatin M)	Hs00171165_ml
LIF (leukaemia inhibitory factor)	Hs00171455_ml
OSMR (oncostatin M receptor)	Hs00384278_ml
LIFR (leukaemia inhibitory factor receptor)	Hs00158730_ml
IL-10 (interleukin 10)	Hs00174086_ml
IL-12a (interleukin-12 chain a)	Hs00168405_ml
IL-12b (interleukin-12 chain b)	Hs00233688_ml
IL-32 (interleukin-32)	Hs00170403_ml
GM-CSF (granulocyte macrophage-colony stimulating factor)	Hs00171266_ml
IFN- γ (interferon gamma)	Hs00174143_ml
CCL2 (monocyte chemoattractant protein 1)	Hs00234140_ml
CX3CL1 (fractalkine)	Hs00171086_ml
CXCL5 (epithelial-derived neutrophil activating protein 78) (ENA-78)	Hs00607029_g1
CCL5 (regulation on activation normal T cell expressed and secreted) (RANTES)	Hs00174575_ml
CXCL8 (IL-8)	Hs00174103_ml
CXCL10	Hs00171042_ml
Leptin	Hs00174877_ml
LeptinR (leptin receptor)	Hs00174497_ml
ADIPOR1 (adiponectin receptor-1)	Hs00360422_ml
ADIPOR2 (adiponectin receptor-2)	Hs00226105_ml
Visfatin	Hs00237184_ml
INSR (insulin receptor)	Hs00169631_ml
RAGE (receptor for advanced glycation end products)	Hs00153957_ml
CD14	Hs00169122_g1
Control genes	
GAPDH (glyceraldehyde-3-phosphate-dehydrogenase)	Hs99999905_ml
18S	Hs99999901_s1
RNA pol II	Hs00222679_ml

Table 2. Immunoregulatory genes that are upregulated by both *Porphyromonas gingivalis* and *Escherichia coli* lipopolysaccharide (LPS).

Gene	Fold change		Fold change		Fold change		Fold change	
	0.5 h		2 h		6 h		24 h	
	<i>P. gingivalis</i>	<i>E. coli</i>	<i>P. gingivalis</i>	<i>E. coli</i>	<i>P. gingivalis</i>	<i>E. coli</i>	<i>P. gingivalis</i>	<i>E. coli</i>
IL-1 family								
IL-1 α	25.5 \pm 9.4	18.6 \pm 10.2	1904 \pm 624	1443.2 \pm 1001.1	78.2 \pm 32.2	245.1 \pm 49.5	10.6 \pm 2.1	41.9 \pm 18.5
IL-1 β	26.7 \pm 17.8	70.3 \pm 29.2	470 \pm 121	1125.1 \pm 894.3	47.0 \pm 13.7	472.2 \pm 290.2	26.8 \pm 12.3	389.2 \pm 78.2
IL-18R	0.8 \pm 0.4	0.8 \pm 0.5	108 \pm 90.3	149.2 \pm 103.6	99.4 \pm 87.7	44.0 \pm 26.5	28.8 \pm 22.8	74.0 \pm 40.6
IL-18Acp	0.4 \pm 0.04	0.7 \pm 0.3	71.8 \pm 29.0	159.5 \pm 144.3	26.1 \pm 10.7	35.3 \pm 21.5	3.7 \pm 1.5	7.6 \pm 5.1
IL-1F9	1.1 \pm 0.3	1.2 \pm 0.6	37.1 \pm 4.5	62.1 \pm 25.9	4.5 \pm 2.1	3.2 \pm 2.1	2.1 \pm 1.1	1.7 \pm 0.8
IL-6 family								
IL-6	0.2 \pm 0.0	1.0 \pm 0.2	1325 \pm 1009.3	52.2 \pm 28.8	12.0 \pm 7.5	788.1 \pm 442.1	6.3 \pm 4.2	135.3 \pm 117.1
LIF	2.1 \pm 1.0	0.8 \pm 0.3	293.1 \pm 218.4	607.4 \pm 546.1	3.8 \pm 3.0	12.9 \pm 8.3	2.6 \pm 1.9	13.1 \pm 0.6
TNF family								
TNF- α	20.1 \pm 13.4	41.7 \pm 12.5	77.8 \pm 30.9	109.3 \pm 82.1	2.3 \pm 0.9	6.2 \pm 1.7	1.2 \pm 0.6	2.6 \pm 0.5
TNFRSF1B	0.7 \pm 0.2	0.7 \pm 0.3	0.3 \pm 0.1	2.7 \pm 2.2	1.1 \pm 0.2	3.7 \pm 0.8	2.4 \pm 0.1	8.5 \pm 1.8
Chemokines								
CCL2	2.3 \pm 1.1	1.9 \pm 0.7	26.9 \pm 14.5	8.6 \pm 5.0	129.1 \pm 72.3	56.3 \pm 20.7	89.8 \pm 47.2	21.0 \pm 18.2
CXCL8	7.8 \pm 4.7	13.2 \pm 4.9	20.9 \pm 4.8	43.0 \pm 33.0	4.8 \pm 2.4	17.7 \pm 6.3	2.3 \pm 0.9	6.9 \pm 1.1
CXCL10	13.0 \pm 6.1	14.7 \pm 11.4	469.5 \pm 160.1	73.4 \pm 45.4	2476 \pm 1566	503.3 \pm 37.5	1086.1 \pm 736.0	93.5 \pm 77.9
Other cytokines								
IL-10	1.3 \pm 0.6	1.1 \pm 0.32	7.5 \pm 2.8	2.9 \pm 0.7	4.4 \pm 0.4	27.7 \pm 11.9	3.8 \pm 0.5	13.3 \pm 1.8
IL-12B	2.6 \pm 1.6	2.6 \pm 0.9	794.2 \pm 541.1	570.2 \pm 288	137.0 \pm 17.3	686.1 \pm 157.3	9.1 \pm 5.1	127.3 \pm 118.0
IL-32	1.0 \pm 0.7	1.5 \pm 0.7	48.5 \pm 22.2	40.0 \pm 17.7	67.1 \pm 35.3	118.0 \pm 55.2	433.5 \pm 56.7	247.2 \pm 145.1

THP-1 monocytes were treated with LPS (100 ng/ml) from either *P. gingivalis* or *E. coli* for the times indicated above. Gene expression was quantified using *Taqman* low-density arrays by real-time polymerase chain reaction and normalized to RNA polymerase II. The values shown are the mean fold change compared with untreated cells \pm standard deviation. These results were obtained from three independent experiments. IL, interleukin; TNF, tumour necrosis factor; TNFRSF1B, TNF alpha receptor superfamily 1B; LIF, leukaemia inhibitory factor.

Measurement of cytokines and chemokines secreted by myeloid cells

The concentrations of CXCL5, CXCL8, IL-1 β and TNF- α in culture supernatants were measured by enzyme-linked immunosorbent assay using commercially available kits (DuoSet; R&D Systems, Abingdon, Oxford, UK). Each sample was measured in duplicate and results were obtained from three independent experiments.

Statistical analyses

Statistically significant differences between groups and over time were assessed using ANOVA with Bonferroni *post-hoc* corrections. For non-parametric data, the Kruskal–Wallis test and Mann–Whitney *U*-test were used.

Results

Regulation of gene expression by *P. gingivalis* and *E. coli* LPS

The temporal regulation of cytokine-related genes in THP-1 monocytes following treatment with *P. gingivalis* or *E. coli* LPS for 0.5, 2, 6 and 24 h was assessed using TLDA. Fifteen

of the 45 different genes represented on the arrays (Table 1) were up-regulated by both types of LPS compared with unstimulated cells. These genes included those encoding mediators with well-established roles in chronic inflammation and the pathogenesis of periodontal disease (e.g. IL-1 β , IL-6 and TNF- α) (Table 2). Some of these genes were up-regulated maximally 2 h after stimulation with LPS, for example IL-1 α , IL-1 β , IL-18 receptor (IL-18R) and CXCL8. Other genes were up-regulated maximally after 6 h, such as IL-6, IL-10 and CCL2, while IL-32 was expressed most highly 24 h post-stimulation (Table 2). Eight of the genes investigated were found to be up-regulated significantly more highly by *E. coli* LPS compared with *P. gingivalis* LPS (Table 3). These included the IL-1 family cytokine IL-1 family (IL-1F)8, the haematopoietic growth factor GM-CSF and the chemokines CCL5, CX3CL1 and CXCL5. Some of these differentially regulated genes were induced most highly 2 h after stimulation with LPS, for example oncostatin M, while other genes were up-regulated maximally after 6 h (GM-CSF) and 24 h (visfatin) post-stimulation. Eighteen of the genes assessed were expressed but were not regulated by either type of LPS. Of the remaining genes, four were not expressed constitutively or were not induced in monocytes (IL-1F10, IL R-related protein 2, IFN- γ and leptin).

Table 3. *Escherichia coli* lipopolysaccharide (LPS) upregulates differentially a subset of genes compared with *Porphyromonas gingivalis* LPS.

Gene	Fold change		Fold change		Fold change		Fold change	
	0.5 h		2 h		6 h		24 h	
	<i>P. gingivalis</i>	<i>E. coli</i>	<i>P. gingivalis</i>	<i>E. coli</i>	<i>P. gingivalis</i>	<i>E. coli</i>	<i>P. gingivalis</i>	<i>E. coli</i>
IL-1 family								
IL-1F8	0.0 ± 0.0	2.7 ± 1.1	0.0 ± 0.0	3.8 ± 0.8	0.8 ± 0.0	1.7 ± 0.7	0.0 ± 0	101.1 ± 62.0
IL-6 family								
OSM	3.0 ± 2.0	3.4 ± 1.5	0.9 ± 0.2	8.2 ± 5.9	0.1 ± 0.0	0.2 ± 0.1	0.1 ± 0.1	1.7 ± 0.9
OSMR	0.3 ± 0.1	0.5 ± 0.2	0.3 ± 0.0	6.4 ± 4.6	0.8 ± 0.3	5.5 ± 1.2	2.8 ± 1.4	8.0 ± 2.4
Chemokines								
CCL5	0.6 ± 0.2	0.7 ± 0.1	1.3 ± 0.2	11.6 ± 8.3	1.2 ± 0.2	9.7 ± 4.3	2.7 ± 0.7	10.4 ± 3.8
CXCL5	0.0 ± 0.0	0.0 ± 0.0	1.0 ± 0.0	1.0 ± 0.0	1.2 ± 0.2	6.3 ± 2.1	1.0 ± 0	27.5 ± 5.1
CX3CL1	0.0 ± 0.0	0.0 ± 0.0	2.0 ± 0.4	35.6 ± 17.0	2.1 ± 0.3	3.9 ± 0.6	0.0 ± 0	0.0 ± 0.0
Other cytokines								
GM-CSF	0.0 ± 0.0	0.0 ± 0.0	12.9 ± 7.6	58.1 ± 6.5	2.4 ± 1.3	161 ± 52.1	3.0 ± 1.0	105.2 ± 68.8
PBEF/visfatin	0.6 ± 0.2	0.8 ± 0.1	1.3 ± 0.3	2.2 ± 0.4	1.6 ± 0.5	5.1 ± 2.3	2.3 ± 0.6	15.2 ± 4.2


THP-1 monocytes were treated with LPS (100 ng/ml) from either *P. gingivalis* or *E. coli* for the times indicated above. Gene expression was quantified using *Taqman* low-density arrays by real-time polymerase chain reaction. The values shown are the mean fold change compared with untreated cells ± standard deviation. These results were obtained from three independent experiments. IL, interleukin; OSM, oncostatin M; OSMR, oncostatin M receptor; GM-CSF, granulocyte–macrophage colony-stimulating factor; PBEF, pre-B cell colony-enhancing factor.

The CXCL5 is regulated differentially by *P. gingivalis* and *E. coli* LPS

The array data showed that the chemokine CXCL5 was up-regulated more highly by LPS from *E. coli* than *P. gingivalis* (Table 3). This pattern of expression emerged 6 h post-stimulation with LPS (Table 3). Single-assay real-time PCR confirmed the data obtained from the TLDA (Fig. 1a). Secreted protein levels of CXCL5 were also measured and showed a similar pattern of regulation by LPS (Fig. 1b). At both the mRNA and protein levels, significant differences in CXCL5 expression were detected 48 h post-stimulation (Fig. 1a and b). These data were obtained using

the human THP-1 monocytic cell line. Therefore, further experiments were performed to establish whether similar expression patterns were observed for CXCL5 expression in primary cells. Primary human monocytes were treated with LPS from either *P. gingivalis* or *E. coli* for 3–48 h. The untreated cells secreted high levels of CXCL5 (Fig. 1c), and these levels were increased in monocytes treated with *P. gingivalis* and *E. coli* LPS. Following 24 h of treatment with *E. coli* LPS, there was a significant increase in CXCL5 levels compared with CXCL5 levels from monocytes treated with *P. gingivalis* LPS or the untreated control cells. MDDCs also expressed CXCL5 constitutively (Fig. 1d) and secreted levels of this cytokine were up-regulated significantly by *E. coli*

Fig. 1. CXCL5 is differentially regulated by *Porphyromonas gingivalis* and *Escherichia coli* lipopolysaccharide (LPS) in myeloid cells. (a) Real-time reverse transcription–polymerase chain reaction analysis of CXCL5 expression using cDNA derived from THP-1 monocytes. Cells were treated with *E. coli* LPS (100 ng/ml) or *P. gingivalis* LPS (100 ng/ml) until the indicated time-points. Enzyme-linked immunosorbent assay was used to measure secreted CXCL5 in culture supernatants from (b) THP-1 monocytes, (c) peripheral blood monocytes and (d) monocyte-derived dendritic cells. The results were obtained from three independent experiments and are presented as average ± standard deviation.






Fig. 2. *Porphyromonas gingivalis* and *Escherichia coli* lipopolysaccharide (LPS) up-regulate interleukin (IL)-1 β and tumour necrosis factor (TNF)- α (a,c) Real-time reverse transcription–polymerase chain reaction was used to quantify IL-1 β and TNF- α using *Taqman* low-density arrays with cDNA derived from THP-1 cells treated with either *P. gingivalis* or *E. coli* LPS. The results were normalized to RNA polymerase II and calculated as a fold change compared with results obtained from unstimulated cells. (b,d) IL-1 β and TNF- α levels in culture supernatant from the THP-1 cells treated with either *P. gingivalis* or *E. coli* LPS, measured by enzyme-linked immunosorbent assay. The results were obtained from three independent experiments and are presented as average \pm standard deviation.

LPS compared with *P. gingivalis* LPS and untreated controls (48 h).

The CXCL5 secretion does not occur via an IL-1 β - or TNF- α -dependent mechanism

The differential regulation of CXCL5 in myeloid cells occurs relatively late (24–48 h) compared with other cytokines; for example, CCL5 is expressed maximally 2 h post-stimulation. It is possible that this effect may not be a direct result of TLR stimulation but may occur indirectly through induction of other proinflammatory cytokines. Previously, IL-1 β and TNF- α have been shown to regulate CXCL5 expression in the A459 pulmonary epithelial cell line [21]. The TLDA data show that both IL-1 β and TNF- α were up-regulated highly by both *P. gingivalis* and *E. coli* LPS at the mRNA level (Fig. 2a and c). Real-time PCR showed that after 24 h, IL-1 β levels induced by *E. coli* LPS were higher than those induced by *P. gingivalis* LPS. Secreted IL-1 β and TNF- α were both present in the culture supernatants taken from cells treated with both types of LPS (Fig. 2b and d). However, there was no significant difference in the levels of these cytokines produced in response to either *P. gingivalis* or *E. coli* LPS. When THP-1 monocytes were treated with IL-1 β (250 pg/ml) or TNF- α (500 pg/ml), no secreted CXCL5 was detected. However, CXCL8 was detected in the same culture supernatants (data not shown), demonstrating that the THP-1 monocytes were responsive to both IL-1 β and TNF- α and were incapable of specifically inducing CXCL5 expression.

Regulation of CXCL5 by other TLR ligands

The MPLA is a TLR-4 agonist but studies in mice have demonstrated that this agonist functions with a bias towards the use of the TRIF adaptor [22] and therefore utilizing principally the TRIF–TRAM MyD88-independent pathway. Although TRIF–TRAM mediates TLR-4 signalling it is not involved in TLR-2-mediated gene expression [10]. To investigate if the differential pattern of expression of CXCL5 was mediated via the TRIF adaptor, THP-1 monocytes were treated with either MPLA (1 μ g/ml) or *E. coli* LPS (100 ng/ml) for 48 h, as this was the time at which maximal CXCL5 expression was detected in the previous experiments and at which point differences in expression levels of CXCL5 following *P. gingivalis* and *E. coli* LPS stimulation reached significant levels. MPLA did not induce CXCL5 secretion, although it was induced by two different preparations of *E. coli* LPS (Fig. 3a). However, MPLA induced TNF- α secretion at a similar level to *E. coli* LPS (Fig. 3b) in the same tissue culture supernatants in which CXCL5 levels were measured, indicating that the TRIF–TRAM adaptors are not required for TLR-4-driven CXCL5 in THP-1 monocytes.

Discussion

This study was undertaken to investigate gene expression in monocytes following exposure to PAMPS which exert their effects via TLR-2 and TLR-4, and our data significantly extend current understanding of cytokine responses by monocytes following exposure to LPS. In addition, new data




Fig. 3. CXCL5 expression is not induced by the Toll/interleukin (IL)-1 receptor (TIR) domain-containing adaptor inducing interferon (IFN)- γ (TRIF)-biased Toll-like receptor (TLR)-4 ligand monophosphoryl lipid A (MPLA). THP-1 monocytes were treated with two different preparations of *Escherichia coli* lipopolysaccharide (LPS) (100 ng/ml), either strain 0111:B4 pure (black) or ultrapure LPS (white) or MPLA (1 $\mu\text{g/ml}$) (grey) for 24 or 48 h. (a) CXCL5 levels in culture supernatants following treatment with *E. coli* LPS or MPLA. (b) Tumour necrosis factor- α levels in the same culture supernatants following treatment with the above ligands. The results were obtained from three independent experiments and represent average \pm standard deviation.

are presented which reveal co-ordinate and temporal gene expression of key inflammatory mediators in response to LPS from *P. gingivalis*, an important pathogen associated with chronic periodontitis. Furthermore, our results show that *P. gingivalis* and *E. coli* LPS have differential effects at the molecular level, leading to quantitative differences in gene expression for a subset of cytokine-related genes.

The IL-1 family cytokines have been shown to play an important role in a variety of chronic inflammatory diseases, including periodontitis and rheumatoid arthritis [23,24]. Thus, in periodontitis, IL-1 β and IL-18 levels in gingival crevicular fluid correlate with severity of disease [18]. Both types of LPS up-regulated IL-1 α , IL-1 β , IL-18R, IL-18 R accessory protein (IL-18RAcP) and IL-1F9. Interestingly, certain members of the IL-1 cytokine family such as IL-18, IL-1R, IL-1RAcP and IL-1Ra were not regulated by LPS at the mRNA level. Previously, IL-18 mRNA has been shown to be expressed constitutively in peripheral blood mononuclear cells; however, stimuli such as LPS up-regulate IL-18 secretion [25]. Furthermore, work from our own laboratory has shown that *P. gingivalis* LPS stimulates IL-18 secretion in monocytes [20,26]. These data emphasize the importance of

post-translational mechanisms of cytokine secretion and therefore, although analysis of mRNA expression demonstrates differential cytokine regulation by LPS from different species of bacteria, further differences may be revealed from proteomic analysis.

Both types of LPS significantly up-regulated IL-32 expression compared with the unstimulated cells. This cytokine has been detected in epithelial cells, natural killer cells and T cells and possesses proinflammatory properties such the ability to induce IL-8 and TNF- α [27]. Recently, it has also been reported that IL-32 is expressed by an oral epithelial cell line (H400) in response to LPS from the periodontal pathogens *P. gingivalis* and *F. nucleatum* [28]. These data, together with the finding that IL-32 plays a role in other inflammatory diseases [29,30] and its ability to induce monocyte differentiation [31], suggest that this cytokine may also contribute to the pathogenesis of periodontal disease. Therefore, investigation into the role of this cytokine in periodontitis could provide further understanding of how cytokine networks function in this disease.

Previous research has shown that different types of *E. coli* LPS, acting through TLR-4, induce distinct but overlapping gene expression profiles [32]. Consistent with our findings, chemokines were among the genes which were regulated differentially by LPS [32]. CXCL5 and CXCL8 are both neutrophil chemoattractants and potent angiogenic factors [33,34]. These chemokines act through the same receptor (CXCR2) [35] and are produced concomitantly in response to IL-1 β and TNF- α in pulmonary epithelial cells (A459) [21]. The data from our study show that CXCL8 was up-regulated by both types of LPS, while CXCL5 was up-regulated significantly only by *E. coli* LPS at the mRNA and protein level in both monocytes and dendritic cells. Secretion of CXCL5 following LPS stimulation is a relatively late event (24+ h) compared with other cytokines and therefore may be mediated by other proinflammatory cytokines. In the A459 cell line, which are pulmonary-derived epithelial cells, both IL-1 β and TNF- α were shown to regulate CXCL5 transcription [21]. In our study, both IL-1 β and TNF- α were up-regulated by LPS in monocytes at the mRNA level and were detected in culture supernatants from LPS-treated cells. However, when THP-1 monocytes were treated with either IL-1 β or TNF- α at comparable concentrations to those that were recorded in the supernatants no secreted CXCL5 was detected, although CXCL8 levels were up-regulated by both cytokines. This discrepancy, with respect to previous data obtained in pulmonary epithelial cells, may be due to the differences in cytokine concentrations used. In our study, cells were stimulated with either 250 pg/ml or 500 pg/ml of IL-1 β or TNF- α , whereas the pulmonary epithelial cells were treated with 10–20 ng/ml of IL-1 β and TNF- α [21]. The differences may be due to differential responses to these cytokines by monocytes and pulmonary epithelial cells. Although IL-1 β and TNF- α are not responsible for TLR-mediated CXCL5 expression, we cannot rule out the possi-

bility that this effect is mediated by other proinflammatory cytokines. Studies carried out in fibroblasts with an inactive transforming growth factor- β kinase 1 (TAK1) revealed that CXCL5 belonged to a group of chemokine genes whose expression was suppressed most strongly by this inactive kinase [36]. Furthermore, in fibroblasts CXCL5 expression was shown to be predominantly mediated by the NF- κ B and JNK pathways [36].

The MPLA is a derivative of LPS and is a TLR-4 agonist which is associated with a bias for TRIF signalling [22]. TLR-4 activation occurs via the adaptors MyD88 and TRIF, whereas TLR-2 utilizes only MyD88 [14,16]. Therefore, THP-1 monocytes were treated with MPLA to investigate whether the differential expression induced by *E. coli* LPS compared with *P. gingivalis* LPS is due to the recruitment of TRIF to TLR-4 by *E. coli* LPS. The results showed that CXCL5 was not expressed in response to MPLA. However, TNF- α was produced at similar levels to those induced by *E. coli* LPS, indicating that the selective use of TRIF adaptor by TLR-4 was not the mechanism by which *E. coli* LPS up-regulated CXCL5.

Other cytokines were also expressed differentially in response to *P. gingivalis* and *E. coli* LPS. For some of these genes, differential regulation occurred at an earlier time-point compared with CXCL5. For example, regarding the oncostatin M receptor and GM-CSF, differential regulation was observed 2 h post-stimulation with LPS. Therefore, this points to multiple mechanisms contributing to differential expression in response to these different PAMPS. The data presented here confirm and extend previous information on the effects of different PAMPS on monocytes. Understanding the mechanisms involved in differential responses will be important in deciphering pathogen–host interactions and how these can be manipulated to prevent tissue destruction associated with chronic inflammatory disease.

Acknowledgements

We would like to thank Dr M. Rangarajan, Barts and the London School of Medicine and Dentistry, London, UK for the gift of *P. gingivalis* LPS. This study was supported by UK Department of Health Clinician Scientist Fellowship DHCS/03/G121/46 awarded to Philip Preshaw.

Disclosure

None.

References

- 1 Darveau RP, Tanner A, Page RC. The microbial challenge in periodontitis. *Periodontol* 2000 **1997**; **14**:12–32.
- 2 Gibson FC III, Genco CA. *Porphyromonas gingivalis* mediated periodontal disease and atherosclerosis: disparate diseases with com-

- monalities in pathogenesis through TLRs. *Curr Pharm Des* 2007; **13**:3665–75.
- 3 Preshaw PM, Foster N, Taylor JJ. Cross-susceptibility between periodontal disease and type 2 diabetes mellitus: an immunobiological perspective. *Periodontol* 2000 **2007**; **45**:138–57.
- 4 Takeuchi O, Hoshino K, Kawai T *et al.* Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. *Immunity* 1999; **11**:443–51.
- 5 Darveau RP, Pham TT, Lemley K *et al.* *Porphyromonas gingivalis* lipopolysaccharide contains multiple lipid A species that functionally interact with both Toll-like receptors 2 and 4. *Infect Immun* 2004; **72**:5041–51.
- 6 Hajishengallis G, Tapping RI, Harokopakis E *et al.* Differential interactions of fimbriae and lipopolysaccharide from *Porphyromonas gingivalis* with the Toll-like receptor 2-centred pattern recognition apparatus. *Cell Microbiol* 2006; **8**:1557–70.
- 7 Dixon DR, Darveau RP. Lipopolysaccharide heterogeneity: innate host responses to bacterial modification of lipid A structure. *J Dent Res* 2005; **84**:584–95.
- 8 Bramanti TE, Wong GG, Weintraub ST, Holt SC. Chemical characterization and biologic properties of lipopolysaccharide from *Bacteroides gingivalis* strains W50, W83, and ATCC 33277. *Oral Microbiol Immunol* 1989; **4**:183–92.
- 9 Shapira L, Champagne C, Van Dyke TE, Amar S. Strain-dependent activation of monocytes and inflammatory macrophages by lipopolysaccharide of *Porphyromonas gingivalis*. *Infect Immun* 1998; **66**:2736–42.
- 10 O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. *Nat Rev Immunol* 2007; **7**:353–64.
- 11 Fitzgerald KA, Palsson-McDermott EM, Bowie AG *et al.* Mal (MyD88-adaptor-like) is required for Toll-like receptor-4 signal transduction. *Nature* 2001; **413**:78–83.
- 12 Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. *Nat Immunol* 2001; **2**:835–41.
- 13 Jiang Z, Zamanian-Daryoush M, Nie H, Silva AM, Williams BR, Li X. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NF κ B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. *J Biol Chem* 2003; **278**:16713–19.
- 14 Yamamoto M, Sato S, Hemmi H *et al.* Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. *Science* 2003; **301**:640–3.
- 15 Zhou Q, Amar S. Identification of signaling pathways in macrophage exposed to *Porphyromonas gingivalis* or to its purified cell wall components. *J Immunol* 2007; **179**:7777–90.
- 16 Zhou Q, Desta T, Fenton M, Graves DT, Amar S. Cytokine profiling of macrophages exposed to *Porphyromonas gingivalis*, its lipopolysaccharide, or its FimA protein. *Infect Immun* 2005; **73**:935–43.
- 17 Hajishengallis G, Ratti P, Harokopakis E. Peptide mapping of bacterial fimbrial epitopes interacting with pattern recognition receptors. *J Biol Chem* 2005; **280**:38902–13.
- 18 Foster N, Cheetham J, Taylor JJ, Preshaw PM. VIP inhibits *Porphyromonas gingivalis* LPS-induced immune responses in human monocytes. *J Dent Res* 2005; **84**:999–1004.
- 19 Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and

- downregulated by tumor necrosis factor alpha. *J Exp Med* 1994; **179**:1109–18.
- 20 Foster N, Lea SR, Preshaw PM, Taylor JJ. Pivotal advance: vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. *J Leukoc Biol* 2007; **81**:893–903.
- 21 Chang MS, McNinch J, Basu R, Simonet S. Cloning and characterization of the human neutrophil-activating peptide (ENA-78) gene. *J Biol Chem* 1994; **269**:25277–82.
- 22 Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. *Science* 2007; **316**:1628–32.
- 23 Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. *Clin Exp Immunol* 2007; **149**:217–25.
- 24 Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. *Semin Nephrol* 2007; **27**:98–114.
- 25 Puren AJ, Fantuzzi G, Dinarello CA. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. *Proc Natl Acad Sci USA* 1999; **96**:2256–61.
- 26 Foster N, Andreadou K, Jamieson L, Preshaw PM, Taylor JJ. VIP inhibits *P. gingivalis* LPS-induced IL-18 and IL-18BP_a in monocytes. *J Dent Res* 2007; **86**:883–7.
- 27 Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. *Ann Rheum Dis* 2006; **65** (Suppl. 3):iii61–4.
- 28 Milward MR, Chapple IL, Wright HJ, Millard JL, Matthews JB, Cooper PR. Differential activation of NF-kappaB and gene expression in oral epithelial cells by periodontal pathogens. *Clin Exp Immunol* 2007; **148**:307–24.
- 29 Shioya M, Nishida A, Yagi Y *et al.* Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. *Clin Exp Immunol* 2007; **149**:480–6.
- 30 Shoda H, Fujio K, Yamaguchi Y *et al.* Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. *Arthritis Res Ther* 2006; **8**:R166.
- 31 Netea MG, Lewis EC, Azam T *et al.* Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. *Proc Natl Acad Sci USA* 2008; **105**:3515–20.
- 32 Chen C, Coats SR, Bumgarner RE, Darveau RP. Hierarchical gene expression profiles of HUVEC stimulated by different lipid A structures obtained from *Porphyromonas gingivalis* and *Escherichia coli*. *Cell Microbiol* 2007; **9**:1028–38.
- 33 Koch AE, Polverini PJ, Kunkel SL *et al.* Interleukin-8 as a macrophage-derived mediator of angiogenesis. *Science* 1992; **258**:1798–801.
- 34 Koch AE, Volin MV, Woods JM *et al.* Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. *Arthritis Rheum* 2001; **44**:31–40.
- 35 Wuyts A, Proost P, Lenaerts JP, Ben-Baruch A, Van Damme J, Wang JM. Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78. *Eur J Biochem* 1998; **255**:67–73.
- 36 Thieffes A, Wolter S, Mushinski JF *et al.* Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor [corrected] target genes. *J Biol Chem* 2005; **280**:27728–41.